VivoSeq
Oncology

Advanced/metastatic Solid Tumors

1

Pipeline Programs↗

44

Active Trials↗

21

Companies Involved↗

Advanced/Metastatic Solid Tumors is an early-stage landscape with 1 program across 21 companies. The most active players are Shanghai Henlius Biotech, Merck & Co., Chongqing Precision Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalC

Chongqing Precision Biotech Co., Ltd

0 programs

PreclinicalN

NiKang Therapeutics, Inc.

0 programs

PreclinicalJ

Jiangsu vcare pharmaceutical technology co., LTD

0 programs

PreclinicalD

Danatlas Pharmaceuticals Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

HLX48

Shanghai Henlius Biotech

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

68

clinical trials

Recruiting35 · 51%
Terminated10 · 15%
Completed10 · 15%
Active, not recruiting7 · 10%
Unknown status4 · 6%
Not yet recruiting2 · 3%

Clinical Trials

Trial Activity

68 trials

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Recruiting·DDualityBio Inc.·Phase 2·NCT06953089·492 enrolled
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Recruiting·QQurgen Inc.·Phase 1·NCT06873659·96 enrolled
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Recruiting·DDualityBio Inc.·Phase 1·NCT07141706·233 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Recruiting·NNiKang Therapeutics, Inc.·Phase 1·NCT06586957·150 enrolled
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
Recruiting·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 2·NCT06413615·150 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Recruiting·CConjupro Biotherapeutics, Inc.·Phase 1·NCT07424547·386 enrolled
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Recruiting·QQurgen Inc.·Phase 1·NCT05989724·150 enrolled
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Recruiting·AAntengene Biologics Limited·Phase 1·NCT05718895·156 enrolled
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Recruiting·WWilliams Cancer Foundation·Phase 1·NCT05544240·20 enrolled
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06010875·48 enrolled
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
Recruiting·National Cancer Centre, Singapore·Phase 1·NCT06587295·40 enrolled
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT06660654·200 enrolled
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Recruiting·PPhrontline Biopharma·Phase 1·NCT07181473·200 enrolled
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07288957·266 enrolled
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT05853367·178 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)